New lineup of TVs and sound devices delivers premium visual and audio experiences supported by AI innovation for an unrivalled home entertainment experience.

SINGAPORE – Media OutReach Newswire – 28 March 2024 – Samsung Electronics Singapore today unveiled its 2024 lineup of Neo QLED 8K, Neo QLED and OLED TVs, as well as their latest sound systems at its Unbox & Discover 2024 Singapore launch held at the iconic Jewel Changi; the event will also be opened to the public on 29 and 30 March, where visitors can experience a new era of AI TVs, as well as partake in exciting activities.

This year’s lineup kicks off the AI screen era through the introduction of a next-generation AI processor poised to redefine the perception of smart display capabilities. In addition to bringing improved picture and sound quality, the new lineups provide consumers with AI-powered features focusing on inspiring and empowering individual lifestyles.

“We are entering a new era of AI, with the technology bringing great potential to improve and add value to our daily lives in both simple and useful ways,” said Steven Koh, Senior Director, Consumer Electronics Business (TV/AV), Samsung Electronics Singapore. “We are excited to wow our consumers with our most cutting-edge TVs, now enhanced with AI, which will not only deliver amazing visual and audio quality for consumers to better enjoy the content that they all love but will also be the ideal centrepiece in consumers’ homes, connecting all compatible devices to offer users a smart and seamless living experience.”

Expect More Wow with Samsung’s New 2024 AI TV Line-up

The QN900D Neo QLED 8K TV and Q990D soundbar delivers exception audio and visual quality enhanced by AI.

This year, Samsung is introducing AI technologies to its TV line-up to deliver elevated enhancements for consumers’ home entertainment setups.

Samsung’s newest Neo QLED 8K and 4K TV lineup are equipped with technology that deliver lifelike picture quality and premium audio experiences. The 2024 Neo QLED 8K range, with the QN900D sitting at the top, features Samsung’s latest and most innovative TV processor yet: NQ8 AI Gen3, which has a neural processing unit (NPU) that delivers unprecedented performance upgrades by utilizing 512 neural networks, versus 64 neural networks on last year’s flagship model.

The Neo QLED lineup brings a suite of picture quality and design enhancing features, including 8K AI Upscaling Pro[1], which leverages NQ8 AI Gen3 for enhanced 8K upscaling, sharpening low resolution content so that it is displayed in ultra-high resolution. AI Motion Enhancer Pro solves common issues in fast-paced sporting contents — such as ball distortion — by streaming high-resolution sports matches through this feature[2] powered by NQ8 AI Gen3. The feature automatically detects the sport type and uses deep learning to properly detect the type of ball and enhances the visual accordingly. For consumers who like watching high-adrenaline action content, Real Depth Enhancer Pro adds details to fast-moving scenes with the help of AI to precisely control mini-LEDs by detecting the part of a scene that the human eye would naturally focus on, bringing it to the foreground. This way, images are more lifelike as there is more depth to the onscreen content. Infinity Air Design complements Neo QLED 8K’s impeccable picture quality with a screen only 12.9mm in depth[3], allowing for an immersive viewing experience that focuses on high resolution and outstanding sound quality. It also offers a unique mirror effect in which the TV appears to hover in its surroundings.

At the same time, the Neo QLED 8K lineup offers exceptional audio quality, with Q-Symphony allowing users to connect multiple wireless speakers and a soundbar to a TV or projector for perfect audio synchronization across shows, movies, and playlists[4]. Users can also take advantage of Active Voice Amplifier Pro, a proprietary AI dialogue booster that utilises exclusive deep-learning technology to significantly enhance dialogue and voices on screen.

Samsung’s S95D OLED TV delivers exceptional visual quality with AI-enhanced colour accuracy.

Samsung’s 2024 OLED TVs build on the legacy of last year’s models, with the S95D offering sizes of up to 77-inches for high-detail, a high-frame rate, and intensely vibrant video. New OLED Glare Free’ technology[5] — specifically designed for 2024 OLED screens — preserves colour accuracy and reduces reflections while maintaining image sharpness to ensure an immersive viewing experience, even in daylight. The OLED-optimised, low-reflection coating overcomes the trade-off between gloss and reflection thanks to a new, specialised hard-coating layer and surface coating pattern.

In addition, the display is 20% brighter than previous models, with deep and rich blacks and AI-enhanced colour accuracy so pure that it is Pantone Validated™. In addition to being Samsung’s brightest OLED screen yet, it also features high refresh rates of up to 144Hz for more seamless motion and crystal-clear action on their screens. Samsung also offers the more wallet friendly S90D series, which will be available in various sizes, from 48″ to 83”.

To complete your home entertainment audio experience, the new flagship Q Series (HW-Q990D) soundbar delivers an 11.1.4-channel sound experience with True Dolby Atmos sound at 4K 120Hz, tapping on AI to optimise sound for the perfect experience, whatever your preferred content.

Unbox & Discover at Jewel Changi

On 29 and 30 March 2024, consumers can visit the Unbox & Discover event held at Jewel Changi Cloud9 Piazza (located at level 5) to experience the new TV and sound systems lineup.

During the two-day event, visitors can learn more about the new products and how they are the ideal complement for today’s home entertainment experiences through daily product experience tours. Visitors can redeem cool gifts such as tote bags which comes printed with local artworks from National Gallery Singapore.

To raise awareness towards sustainability, Samsung Singapore is working in partnership with the National Environment Agency to collect used batteries. In exchange for at least 4 batteries[6], visitors can receive a foldable reusable bag, limited to 1 redemption per person. The event hopes to break Singapore’s record for the most batteries collected as a way to encourage and inspire like-minded individuals to practise sustainability in their day-to-day lifestyle.

Preorder Promotions

Customers who pre-order a Samsung AI-powered TV can enjoy gifts worth up to $3,933, until 11 April 2024[7].

Model	Size	Pre-order Offer
Samsung Neo QLED 8K	75″, 85″	Mystery gift + Freestyle 2nd Gen (worth $1,513)
	65″	Mystery gift
Samsung Neo QLED 4K	75″, 85″	Mystery gift + Freestyle 2nd Gen (worth $1,513)
	55″, 65″	Mystery gift + Nintendo Switch (worth $399)
	43″, 50″	Slimfit Cam (worth $202)
Samsung OLED 4K	77″	Mystery gift + Freestyle 2nd Gen (worth $1,513)
	55″, 65″	Mystery gift + Nintendo Switch (worth $399)

For more information about the 2024 TV and sound systems line-up, please visit www.samsung.com/sg.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

Hashtag: #Samsung

The issuer is solely responsible for the content of this announcement.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

Creating a convenient nutritional supplement experience for urban dwellers with specific health goals

HONG KONG SAR – Media OutReach Newswire – 28 March 2024 – HKT (SEHK: 6823) – DrGo, HKT’s one-stop telemedicine platform, announced the launch of DrGo Me+ Ready Pack, a new portable nutritional supplement pack that allows users to easily obtain professionally designed and recommended nutritional supplements.

Professional, efficient nutritional supplement pack to help relieve urban stress

The DrGo Me+ Ready Pack series includes the Stress Relief Pack, Women’s Essential Pack and Liver Detox Pack (coming soon), all designed and recommended by a Hong Kong nutritionist for specific health goals¹. Each box of Ready Pack contains 30 individually packaged nutritional supplement packs, each containing four different nutritional supplements recommended by the nutritionist, and comes with delivery service². Users can simply consume one small pack per day to easily meet their daily nutritional supplement needs, sparing them from the hassle of storing and carrying multiple bottles of different nutritional supplements.

DrGo Me+ Ready Pack	Suitable users & benefits	Included supplements
Stress Relief Pack	Suitable for individuals with busy lifestyles and difficulties concentrating and relaxing Helps relieve stress, reduce fatigue and enhance memory	Resveratrol Acetyl L-Carnitine Turmeric with Black Pepper Zinc
Women’s Essential Pack	Specifically designed for women looking to strengthen their body and increase vitality Helps restore energy, boost blood circulation and skin health, improve sleep quality and relieve stress	Iron Vitamin C with Rose Hips Astaxanthin Resveratrol
Liver Detox Pack (coming soon)	Suitable for individuals who smoke or drink excessively with irregular mealtime and a busy social calendar Enhances liver detoxification and intestinal excretion, boosts metabolism and improves digestion and nutrient absorption	Vitamin B Complex Vitamin C with Rose Hips Turmeric with Black Pepper Probiotics

DrGo Me+ nutritional supplements have GMP quality assurance³, undergo strict quality control and expert inspection, and are tested for purity and efficacy by third-party laboratories⁴. The packaging process complies with the ISO22000 international food safety management system standard⁵, ensuring the safety of the supplements and providing peace of mind for users.

Teresa Ng, Chief Commercial Officer, DrGo said, “The newly launched portable nutritional supplement pack, DrGo Me+ Ready Pack, further enriches DrGo’s product offerings and enhances its ability to reach a wider customer base and increase user adoption on the platform. We will continue to dedicate ourselves to innovative services and products with the goal of meeting users’ diverse needs for a healthy lifestyle through a unified platform. This will foster greater user loyalty and create more opportunities for cross-selling.”

Two flexible and convenient purchase options

Catering to the diverse needs of users, the Ready Pack offers two purchasing options: a One-time Solution containing 30 packs and an automatic recurring subscription plan spanning 1 month or 3 months⁶, ensuring that users’ health regimen will not be interrupted.

From now until 30 June 2024, DrGo Me+ Ready Pack is offering a promotional price for One-time Solution at HK$299 per box (listed price: HK$336), and customers will enjoy an additional 10% or 25% off when purchasing 1-Month or 3-Month Solution with the discount code “NEWBIE” or “NEWBIEME” respectively⁷.

To experience the DrGo Me+ Ready Pack, please visit DrGo website at

https://www.drgohealthstore.com.hk/meplus-supplement/⁸.

To register with DrGo, please download the DrGo app at

https://drgohkt.page.link/download_app. For more details, please call DrGo’s service hotline at +852 2380 2323 or visit DrGo’s website at

https://www.drgo.com.hk/index_en.html.

Notes:

1. Supplements in the Ready Packs series were designed and recommended by nutritionist Mandy Wong.

2. Delivery service is limited to designated local locations. For details, please see DrGo Me+ website or DrGo app for the “DrGo Me+ Delivery Policy”.

3. The information is provided by the manufacturer of the supplements.

4. The information is provided and endorsed by the Testing Centre.

5. The information is provided by the packaging company.

6. Under such subscription plan, customers will be subject to automatic successive renewals of their 1-Month or 3-Month Solution every 30 days (for 1-Month Solution) or every 90 days (for 3-Month Solution) at the prevailing price at the time of the renewal for the relevant Solution as indicated on the DrGo Me+ website or DrGo app, unless the customer has validly terminated the subscription.

7. Promotion will end on 30 June 2024. Customer may enter the designated coupon code in “Apply Coupon Code” column at checkout to enjoy this offer. The offer is subject to relevant terms and conditions. For details, please see DrGo Me+ website or DrGo app.

8. All information, recommendation and statements provided under DrGo Me+, including, without limitation, any packaging information and labelling are for information only and any supplement and recommendations are merely recommendation only, all of which are not in any way intended to prevent, diagnose, treat or cure any illness. Supplements recommended by DrGo Me+ are not registered under the Pharmacy and Poisons Ordinance nor the Chinese Medicine Ordinance. Any claim made for or in relation to such supplements has not been subject to evaluation for such registration.

Hashtag: #DrGo

The issuer is solely responsible for the content of this announcement.

About HKT

HKT is a technology, media, and telecommunication leader with more than 150 years of history in Hong Kong. As the city’s true 5G provider, HKT connects businesses and people locally and globally. Our end-to-end enterprise solutions make us a market-leading digital transformation partner of choice for businesses, whereas our comprehensive connectivity and smart living offerings enrich people’s lives and cater for their diverse needs for work, entertainment, education, well-being, and even a sustainable low-carbon lifestyle. Together with our digital ventures which support digital economy development and help connect Hong Kong to the world as an international financial centre, HKT endeavours to contribute to smart city development and help our community tech forward.

For more information, please visit www.hkt.com.

LinkedIn: linkedin.com/company/hkt

About DrGo

Powered by HKT, DrGo is an end-to-end app-based healthtech platform offering one-stop telemedicine consultation and diversified healthcare services through partnership with healthcare professionals, including registered medical practitioners and listed Chinese medicine practitioners. Leveraging HKT’s state-of-the-art technology, the entire consultation journey is encrypted to protect users’ privacy. By offering DrGo Me+ Personalised Supplement Pack and Ready Pack, DrGo enables users to safeguard their well-being with ease and convenience.

SINGAPORE – Media OutReach Newswire – 28 March 2024 – Don’t Worry, Shop Shopee! The wait is over as Shopee gears up for 4.4 Shopee Spree. Mark your calendars from March 28th to April 4th. Beyond unbeatable deals, exclusive offers, and exciting rewards, get ready to experience peace-of-mind shopping as Shopee rolls out delivery and return policies.

This 4.4 Spree, shop worry-free with Shopee’s 15-Day Free Returns, No Questions Asked* policy. Make purchases with the assurance that you can easily exchange or get a refund if your purchases are unsuitable for your needs. Shop confidently and explore a wide range of products without any concerns about making the wrong choice.

But wait, there’s more. For those who just can’t wait for their parcels, opt for Guaranteed Next Day Delivery to be able to enjoy your purchases the very next day! Throughout the campaign, shoppers can also enjoy an impressive 20% cashback on selected items across the platform. Cart out lowest prices bestseller deals from favourite brands like Samsung, Tefal, Medicube, Skechers, Aptamil Dumex, Asus and more!

From March 28th to April 4th, shoppers can also explore Flash Deals Spree at up to seven time slots, featuring cashback vouchers and curated deals refreshed daily.

Voucher lovers can look forward to using the following Shopee vouchers at checkout to unlock even greater discounts.

• Upsized Vouchers: Get ready for upsized voucher drops throughout the day.
• Brands Vouchers: Top brands with additional stackable vouchers with 10% and 8% off storewide.
• Vouchers on Shopee LIVE: Catch the hottest deals on live streams with Upsized 50% Cashback vouchers dropped hourly from 11am!

Experience the excitement of the the 4.4 Shopee Spree now at: https://shopee.sg/m/4-4

* Terms and Conditions apply
Hashtag: #Shopee

The issuer is solely responsible for the content of this announcement.

About Shopee

Shopee is the leading e-commerce platform in Southeast Asia & Taiwan. Shopee promotes an inclusive and sustainable digital ecosystem by enabling businesses to digitalise and grow their online presence, helping more people access and benefit from digital services, and uplifting local communities.

Shopee offers an easy, secure, and engaging experience that is enjoyed by millions of people daily. Shopee is also a key contributor to the region’s digital economy with a firm commitment to helping homegrown brands and entrepreneurs succeed in e-commerce.

Shopee is part of Sea Limited (NYSE: SE), a leading global consumer internet company. Sea’s mission is to better the lives of consumers and small businesses with technology through its three core businesses: Shopee, Garena and SeaMoney.

The Group Recorded Revenue of Approximately HK$1,200 million Net Profit for FY2023 increased more than 5.8 times YoY Business is booming and Sales in Southeast Asia doubled Leading the Group to Reach New Heights

HONG KONG SAR – Media OutReach Newswire – 28 March 2024 – Tycoon Group Holdings Limited (“Tycoon Group” or the “Group“, Stock Code: 3390.HK), an omnichannel brand marketing and management service integrator of health products in Hong Kong, announced its audited consolidated annual results for the year ended 31 December 2023 (the “Financial Year” or “FY2023“).

In 2023, Hong Kong’s economy began its journey towards recovery. The number of visitors returning to Hong Kong continued to rise, and the Southeast Asian markets were also recovering rapidly. These positive developments provided further support for local consumption. During the Financial Year, the Group has achieved steady growth in revenue and continues to generate profit. In FY2023, the Group recorded revenue of approximately HK$1,198.6 million, an increase of 1.1% from the year ended 31 December 2022 (“Last Financial Year” or “FY2022”) of HK$1,186.2 million. The Group’s net profit surged to HK$297.3 million (FY2022: HK$43.6 million), representing an increase of 581.4% year-on-year. The gross profit of the Group increased by 22.8% to HK$321.1 million for the Financial Year as compared to that of HK$261.5 million for FY2022, and the gross profit margin increased by 4.8 percentage points to 26.8%. Increase in gross profit and gross profit margin was mainly due to the Group’s continuous efforts in optimising its product portfolio, exploring new markets in Southeast Asia, enhancing its own brands, as well as introducing new own products. These initiatives have led to an increase in overall revenue and gross profit. The Board has recommended to declare a final dividend of HK3.5 cents in cash per ordinary share for FY2023 (FY2022: HK3 cents). Together with the interim dividend of HK3.5 cents per ordinary share, this brings the total dividend for FY2023 to HK7 cents per ordinary share (FY2022 total dividend: HK3 cents).

Building on the rapid growth, the Group will focus its resources on promoting its

distribution business

During the Financial Year, the Group mainly operates three major operating segments, namely distribution business, e-commerce business and retail store business. The full reopening of Hong Kong’s borders at the beginning of the year has bolstered the performance of the Group’s distribution business, maintaining its upward trajectory. In the Financial Year, the Group’s Hong Kong distribution sales reflected a significant 94.0% year-on-year increase. Similarly, the Group’s Macau distribution sales experienced a notable growth rate of 19.1%, attributed to the combined effects of the resumption of cross-border travel between Hong Kong, Macau and Mainland China, and the expansion of the tourism industry in Macau. In addition to its continuous efforts to strengthen its business in Hong Kong, the Group has focused on penetrating the Southeast Asian market in recent years, resulting in a 152.3% year-on-year growth in its Southeast Asia distribution sales.

Considering the rapid growth of the Group’s distribution business, the Group will prioritise allocating resources to drive the distribution business forward. In July 2023, the Group announced the sale of a 51% stake in Combo Win Asia Limited (“CWA”) for a consideration of HK$130 million. The additional proceeds from the sale of the CWA stake will provide the Group with more resources to strengthen its distribution business in Hong Kong, Macau and Southeast Asia, as well as develop its own brands. These initiatives will propel the long-term development of the Group, enrich the Group’s product portfolio, enhance gross profit margins, and achieve even better performance.

In FY2023, the segment result of the e-commerce business amounted to HK$48.4 million (FY2022: HK$40.7 million).

Strengthen well-known best-selling brands marketing and actively develop its own brands

During the Financial Year, the Group continued to develop the omnichannel brand marketing and management business, including one of the global best-selling probiotic brands, Culturelle®; Japanese anti-hair loss and hair protection brand, Kaminowa; and leading French baby washing care brand, Biolane, and more. For Biolane, the Group also has exclusive distribution rights in Singapore and Malaysia.

In addition to its brand agency business, the Group is also actively developing its own brands. The Group has established and developed its own well-received brands of healthcare products, including “Boost & Guard Pro (BG Pro 博健專研)”, “Craft by Wakan (和漢匠心)”, and “Kinmen Qiangxiao (金門強效)”. Among them, “Boost & Guard Pro” and “Craft by Wakan” have quickly responded to market trends by introducing a diverse range of new products, allowing the Group to tap into a broader market of blue ocean.

The Group’s marketing capabilities have also been regonized by renowned brands. The Group has partnered with well-known artistes Mr. Wong Tak Bun, Kenny and Ms. Tse On Kay, Kay. They have successively become the brand ambassadors for the Japanese anti-hair loss and hair protection brand, Kaminowa, in Hong Kong. In terms of own brands, the Group enlisted the support of renowned artiste Ms. Lin Min Chen as the spokesperson for its flagship product “Craft by Wakan Japanese Probiotics”, and invited the popular artiste Mr. Cheung Kai Chung, Louis, to endorse its best-selling brand “Kinmen Qiangxiao”.

In addition, to align with the Group’s strategy of strengthening the development of its own brands, Mr. Wong Ka Chun Michael, the Chairman, Executive Director, and Chief Executive Officer of the Group, personally acquired the well-established Hong Kong brand Po Wo Tong, which has a rich century-old heritage. This acquisition positions Mr. Wong as a major shareholder, enabling collaboration with the Group to launch and sell a wider range of new products. The objective is to reinforce the Group’s portfolio of own brand offerings. Using the proceeds from the previous sale of partial stake in its e-commerce business, the Group is investing more resources in its own brands with higher gross profit margins, and developing and launching more of its own brands and different products to cater for the needs of Mainland visitors travelling under the Individual Visit Scheme (“IVS”) after the reopening of the border, as well as the new trend of the PCM and healthcare products market as a whole.

Focus on business development in Southeast Asia

The Group believes that establishing a presence in Southeast Asia will be advantageous and consequently set up companies in Singapore and Malaysia before going public. The Group will put more resources into the Southeast Asian market and apply the successful distribution model in Hong Kong to its distribution operations in Singapore and Malaysia. The Group aims to partner with prominent personal care product chains in Malaysia and Singapore. Among them is the chain store Guardian, known as Mannings in Hong Kong, which has its headquarters in Hong Kong and has maintained a friendly, cooperative relationship with the Group. This partnership benefits the Group by expanding its sales channels into Southeast Asia, which is expected to become another major profit-contributing region for the Group in the future. In addition, in FY2023, the sales revenue from distribution in Singapore reached HK$41.8 million, representing an increase of 121.3% compared to HK$18.9 million in FY2022. It is anticipated that sales will continue to experience rapid growth in 2024.

Mr. Wong Ka Chun Michael, the Chairman and the Chief Executive Officer of Tycoon Group, said, “2024 is a year of striving for performance, revenue, and growth for the Group. Leveraging the experience and resources accumulated over the past three years of the epidemic, the Group can be anticipated to shine brightly. In addition to its continued focus on development in Hong Kong, Macau, and Mainland China, the Group will strengthen its presence in the Southeast Asian market, particularly in Singapore and Malaysia and expand its international presence. In the local market, the Group has a positive outlook on the market for prepared Chinese herbal medicine and dry supplement products and has been actively expanding its range of supplement products and strengthening its PCM offerings. Let’s anticipate the next fruitful season for the Group as a gesture of appreciation for the trust and support of all shareholders, employees, business partners, and customers.”

Hashtag: #TycoonGroup

The issuer is solely responsible for the content of this announcement.

About Tycoon Group Holdings Limited (Stock Code: 3390)

Tycoon Group is a reputable omnichannel brand marketing and management service integrator of health and well-being related products in Hong Kong. The Group specialises in providing one-stop services for PCM, health supplements, skincare, personal care and other healthcare products, including omnichannel brand agent, marketing, management, distribution and sales. The Group has established a strong online and offline sales network in Hong Kong, Macau, the PRC and Southeast Asia by cultivating the industry for many years with the mission of bringing health and vitality to consumers in Mainland China, Hong Kong, Macau and Asia-Pacific. The Group has provided over 200 local and foreign brands. With a vision of establishing its own brands, the Group developed its own-brand products including “Boost & Guard Pro”, ” Craft by Wakan”, and ” Kinmen Qiangxiao”. Tycoon has established sound relationships with chain retailer customers, with the top two chain retailer customers operating over 470 stores in Hong Kong. The Group is also one of the major distributors for PCM in Hong Kong. For more details, please visit the Group’s official website: https://www.tycoongroup.com.hk/

Launches Blue Cross Elite Combo and Love Yourself VHIS Plan in first quarter of 2024 With “Just Right” protection

HONG KONG SAR – Media OutReach Newswire – 28 March 2024 – Blue Cross (Asia-Pacific) Insurance Limited (“Blue Cross”) achieved a remarkable 17.9% growth in overall business in 2023, surpassing the market’s 6.3% increase¹. Maintaining the growth momentum, Blue Cross announced the launch of two new products: Blue Cross Elite Combo and Blue Cross Love Yourself VHIS Plan. The former introduces a groundbreaking concept of “multiple plans in one single policy, same coverage period, and effortless management”, and is sold exclusively by AIA Hong Kong Financial Planners who have been registered as Blue Cross’s agents. The latter allows flexible adjustment of deductible and offers an affordable, value-for-money choice of medical protection for young adults. Both products feature multiple competitive benefits in the market and cater to the needs of customers with the “just right” protection at the right time for the right budget.

Blue Cross delivered outstanding business results in 2023:

• Overall business grew by 17.9%, well above the 6.3% growth in the market. All product lines outperformed the market in terms of year-on-year growth.
• As a market leader in general insurance, Blue Cross achieved particularly strong growth in the non-medical business, with an impressive growth rate 11 times the market growth rate². Most notable was the travel and personal accident insurance business which surged 270%, quadrupling the market’s 66.1% growth³.
• Medical insurance has always been a growth driver for Blue Cross. Last year also saw steady growth of 8.1%, outperforming the market’s 7.5% growth in the medical business⁴.

Ms Bonnie Tse, Chief Executive Officer of Blue Cross, said, “Upholding its customer-first philosophy, Blue Cross has been serving Hong Kong for over 55 years and leading the industry in developing ‘just right’ products that address the needs and pain points of customers. We have been expanding customer touchpoints to enhance customer experience with seamless services online and offline. Blue Cross outperformed the market in various business segments last year. This remarkable performance is indeed a testimonial to our strategies. I believe there is still huge growth potential in the general insurance and medical insurance markets, and I remain 100% confident in our business outlook.

“Considering customers’ demand for multiple protections and flexible offerings, we have launched two new products, Blue Cross Elite Combo and Blue Cross Love Yourself VHIS Plan. Underlining innovation and flexibility, both products are designed as affordable and value-for-money offerings to address customers’ protection needs at different stages of life.”

Blue Cross Elite Combo
Blue Cross Elite Combo introduces a groundbreaking insurance concept of “multiple plans in one single policy, same coverage period, and effortless management.” It allows customers to freely choose their coverage combination from a range of insurance and customise benefit levels according to their individual needs and budget. The product is highly flexible and accentuates the freedom of choice, providing customers with all-around protection for their everyday lives and appealing to smart individuals, newlyweds as well as three-generation family households. Below are its key features.

• Combining multiple insurance types: The plan covers six different types of insurance with a total of 22 coverage options, providing comprehensive protection for various aspects of daily life. It comprises three Basic Protection Modules – Travel Cover, Home Cover and Domestic Helper Cover, as well as three Supplementary Protection Modules that can be added as needed – Golf Cover, Leased Property Cover and Personal Cover. To enrol in the plan, customers need to choose at least one Basic Protection Module before adding a Supplementary Protection Module.
• Better control over premium budget: Customers can freely customise the desired coverage combination and benefit level of the protection options according to budget.
• Flexibility to change protection combination: Considering that protection needs may change at different stages of life, the plan provides flexibility to change protection combinations according to needs. There are also options for Plan Level (including Sumptuous Choice, Balanced Choice and Light Choice) or Optional Add-ons for customers to choose from, further enhancing their protection and creating a worry-free life for themselves and their families.
• Unified policy management: The plan consolidates multiple coverage plans under just a single policy, with the same coverage period. Coverage renewal can be done together upon expiry, enhancing the convenience and ease of policy management.
• Brand new e-Protection: Catering to today’s prevailing online shopping habit, the plan provides e-Protection under Personal Cover, safeguarding customers against identity theft and financial losses from online purchases.

Blue Cross has also launched a new advertising and marketing campaign “Customise Your Just Right Protection” to promote Blue Cross Elite Combo, featuring the perfect pair of the Blue Cross mascot and a pretty girl. They travel around Hong Kong and showcase unique product features such as its great flexibility and a diverse range of combinations and options which allow customers to customise their “Just Right” protection plan according to their needs and budget. A new video has been posted on social media and digital platforms; there were other promotions on the street to engage the public to bring out the campaign message about Blue Cross Elite Combo. Furthermore, outdoor advertising including tram stations and tram bodies, and MTR ads will soon be launched to extend its reach to the public. To view the video, click:
https://www.facebook.com/share/v/LAjpiWU4YYKJULgX/?mibextid=oFDknk

Blue Cross Love Yourself VHIS Plan
In addition, Blue Cross has launched its Love Yourself VHIS Plan, a voluntary health insurance scheme (VHIS) flexi plan certified by the Health Bureau. It allows flexible adjustment of deductible and offers an affordable, value-for-money choice for young adults. The plan provides full coverage of 17 major medical expenses incurred before, during and after hospital stay (private hospital’s ward), from diagnosis, surgery to recovery. It offers an annual benefit limit of HK$6,000,000 and a lifetime benefit limit of HK$40,000,000, with lifetime renewal guaranteed. The plan features multiple market advantages, which allow customers to customise their own cover by selecting the plan level, deductible amount, optional outpatient benefits and optional dental benefits, and enjoy a range of superb value-added services. Its key features are as follows.

• Flexible adjustment of deductibles at milestone events in life – market-first for VHIS Plans: Considering that the financial needs and responsibilities that one shoulder will change at different milestones in life, the plan provides options for policyholders to reduce or remove the selected deductible without re-underwriting, especially in the significant events of life including having a newborn baby, buying a residential property, moving abroad, or reaching a designated age.
• Deductible waived for specified health conditions: If the insured person is unfortunately diagnosed with designated critical illnesses, sports-related injuries and permanent total disabilities, the related deductible will be waived, providing full support to customers during difficult times.
• Immediate cover for unknown pre-existing and congenital conditions: The plan fully covers unknown pre-existing conditions and congenital conditions which have been diagnosed at or after the age of 8, with coverage starting immediately from day one when the policy becomes effective. No waiting period is required.
• Health & wellness benefit: For every three consecutive years the policy has been in force, customers can get reimbursed for actual expenses of wellness activities incurred within the immediately following policy year, up to HK$1,500. Covering expenses on travelling, fitness gym membership and wellness courses, this benefit aims to encourage customers to lead a healthy lifestyle.
• Various value-added services: These include free second medical opinion, pre-hospitalisation claim assessment, no hospital bills to pay, 24-hour worldwide emergency aid, Blue Cross nursing care hotline etc.

During the promotional period, customers who enrol in Blue Cross Love Yourself VHIS Plan can enjoy a discount of up to 32% on the first-year premium⁵. Moreover, Blue Cross SmartClub members who enrol in Blue Cross Love Yourself VHIS Plan via Blue Cross website or Blue Cross HK App can earn double SmartPoints.

SmartClub members can now redeem a one-day ticket to Hong Kong Disneyland with 10,000 SmartPoints.

The above product information of Blue Cross Elite Combo does not include the full version of the terms and conditions. Please refer to the policy for detailed terms and conditions. For more details, please visit https://www.bluecross.com.hk/en/ePromotion/AIA_GIProducts/latest or contact AIA Hong Kong Financial Planners who have been registered as Blue Cross’s agents or call 2839 6333.

The above product information of Blue Cross Love Yourself VHIS Plan does not include the full version of the terms and conditions. Please refer to the policy for detailed terms and conditions. Promotional offers are subject to the terms and conditions. Please visit Blue Cross website at www.bluecross.com.hk or download the Blue Cross HK App.

Remarks:

1. Source: Provisional statistics on general insurance business (direct business) published by the Insurance Authority for 2023, excluding mortgage guarantee.
2. Source: Provisional statistics on general insurance business (direct business) published by the Insurance Authority for 2023, excluding medical and mortgage guarantee.
3. Source: Provisional statistics on general insurance business (direct business) published by the Insurance Authority for 2023, non-medical subclass in accident and health business.
4. Source: Provisional statistics on general insurance business (direct business) published by the Insurance Authority for 2023, medical subclass in accident and health business.
5. It is calculated based on a 15% discount on first-year premium and up to 15% family discount.

“AIA Hong Kong” herein refers to the Hong Kong Branch and/or Macau Branch of AIA International Limited (Incorporated in Bermuda with limited liability).

“Hong Kong” and “Macau” herein refer to “Hong Kong Special Administrative Region” and “Macao Special Administrative Region”, respectively.

Disclaimers:

• This press release is for distribution in Hong Kong only. The distribution of this press release is not and shall not be construed as an offer to sell or a solicitation to buy or a provision of any insurance product outside Hong Kong.
• Blue Cross (Asia-Pacific) Insurance Limited is a subsidiary of AIA Group Limited. It is not affiliated with or related in any way to Blue Cross and Blue Shield Association or any of its affiliates or licensees.

Hashtag: #BlueCross

The issuer is solely responsible for the content of this announcement.

Blue Cross (Asia-Pacific) Insurance Limited

Blue Cross (Asia-Pacific) Insurance Limited (“Blue Cross”) is a subsidiary of AIA Group Limited. With over 50 years of operational experience in the insurance industry, Blue Cross provides a comprehensive range of products and services including medical, travel and general insurance, which cater to the needs of both individual and corporate customers. Blue Cross distributes its products through various channels, including AIA agency force, online platform, direct sales, BEA network, insurance agents and brokers, as well as travel agencies.

In 2023, Blue Cross is assigned financial strength rating of A+ (stable outlook) and issuer credit rating of A+ (stable outlook) by S&P Global Ratings

JAKARTA, INDONESIA – Media OutReach Newswire – 28 March 2024 – VinFast Auto (Nasdaq: VFS) has officially opened sales of the VF e34, a C-segment electric SUV with a right-hand drive configuration, marking VinFast’s first offering in the Indonesian market. The company has also introduced a unique battery subscription policy that will help reduce upfront purchase costs and highlights VinFast’s commitment to making electric vehicles more accessible to everyone.

VinFast has begun selling the VF e34 in Indonesia, marking a significant milestone in its Southeast Asian expansion. The VF e34 will have a starting list price excluding the battery of IDR 315,000,000.

With the goal of popularizing green mobility and strengthening its competitiveness in Indonesia, VinFast has also launched a unique, groundbreaking battery subscription policy, helping reduce both the upfront purchase price and ongoing running costs.

Customers will pay 1,500,000 IDR per month for up to 3,000 km and 2,600,000 IDR per month for distances over 3,000 km. This approach ensures that the combined cost of the battery subscription and charging remains significantly lower than operating a gasoline car in the same segment for frequent drivers.

According to the battery subscription policy, VinFast will maintain and replace the battery free of charge if capacity falls below 70%, reducing the burden of potential battery degradation repair or replacement costs, as well as ensuring peace of mind for customers throughout the ownership of the VF e34. Additionally, the VF e34 comes with VinFast’s standard 10-year warranty for the vehicle.

Mr. Tran Quoc Huy, VinFast Indonesia CEO, said: “Following our successful debut at the 2024 Indonesia International Motor Show, VinFast is proud to bring its first right-hand drive electric car to Indonesia, marking a significant step in our ambitious expansion plans in Southeast Asia. With the modern, powerful, and capable VF e34 model, we aim to support Indonesian consumers on their journey towards a sustainable transportation future”.

The VF e34 measures 4,300 mm long, 1,793 mm wide, and 1,613 mm tall with a 2,611 mm wheelbase and 180 mm of ground clearance. Equipped with an electric motor with a maximum output of 110 kW and 242 Nm of torque, it utilizes a front-wheel drive system for a smooth and efficient ride. As a result of its 42-kWh battery pack, the VF e34 boasts a range of 318 km on a single charge, making it the perfect companion for daily commutes.

The vehicle is fully equipped with advanced safety features and a suite of user-friendly smart technologies that come standard, including remote software updates, voice control support, battery charging status monitoring, and more. Additionally, the VF e34 boasts theft risk warnings and the ability to remember user usage habits for a more personalized experience.

As VinFast’s first electric vehicle to lead Vietnam’s green transportation revolution, the VF e34 arrives in Indonesia ready to redefine urban mobility. This smart and dynamic SUV promises a new lifestyle for city dwellers, all while accelerating the growth of the Indonesian electric vehicle market. The first VF e34 cars are expected to be delivered to Indonesian customers in the second quarter of this year.

VinFast is targeting expansion to at least 50 countries in 2024. In addition to key markets such as the U.S., Canada, and Europe, VinFast is building its presence in neighboring countries in Southeast Asia such as India, Indonesia, Thailand, and the Philippines, as well as the Middle East and Africa. Alongside its Vietnamese operations, VinFast is also accelerating the construction of manufacturing plants in the U.S. and India, with plans for an additional plant in Indonesia.

Hashtag: #VinFast

The issuer is solely responsible for the content of this announcement.

About VinFast

VinFast – a member of Vingroup – envisioned to drive the movement of the global smart electric vehicle revolution. Established in 2017, VinFast owns a state-of-the-art automotive manufacturing complex with scalability that boasts up to 90% automation in Hai Phong, Vietnam.

Strongly committed to the mission for a sustainable future for everyone, VinFast constantly innovates to bring high-quality products, advanced smart services, seamless customer experiences, and pricing strategy for all to inspire global customers to jointly create a future of smart mobility and a sustainable planet. Learn more at: https://vinfastauto.id/en

Three Highly Anticipated Flagship Upgraded Vaccines Filing for Market Listing; Significant Breakthrough Achieved in the International Market

HONG KONG SAR – Media OutReach Newswire – 28 March 2024 – AIM Vaccine Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce the results for the year ended 31 December 2023 (the “Period”).

As of December 31, 2023, AIM Vaccine has obtained a total of 14 clinical approvals and conducted 21 clinical trials. Among them, 5 vaccine varieties have reached the final stage of Phase III clinical trials. The construction of the production workshops for these 5 vaccine products in Phase III is have been substantially completed, and various preparations for market launch are currently underway. In 2024, the company plans to submit market applications for 3 products and initiate clinical applications for 7 other products.

During the reporting period, the full course of vaccination in Phase III clinical trial of 13-valent pneumonia conjugate vaccine (PCV13) was completed, and we have submitted the pre-application for marketing registration to the NMPA; the full course of vaccination in the subjects in Phase III clinical trial of 23-valent pneumonia polysaccharide vaccine (PPSV23) and iterative serum-free rabies vaccine was completed; EV71-CA16 bivalent HFMD vaccine (HDC) as a global innovative vaccine which is being developed for the first time worldwide has obtained clinical approvals; and iterative mRNA rabies vaccine is the first nonCOVID-19 mRNA vaccine candidate accepted by relevant authorities in China.

According to the announcement, AIM Vaccine has maintained a high level of investment in research and development, with R&D expenses reaching RMB 636.4 million in 2023. This represents a 27.2% increase compared to the same period in 2022. The proportion of R&D revenue stands at 53.6%, positioning the company at the forefront of the industry.

Integrating Industry’s Finest Resources | Abundant Vaccine Pipeline | Multiple Game-Changing Flagship Products Entering Harvest Season

AIM Vaccine is an extremely rare comprehensive vaccine industry group that possesses advantages in four dimensions: pipeline, research and development, production, and sales. Currently, the company has commercialized 8 vaccines targeting 6 disease areas and is developing 21 vaccine candidates. Its pipeline covers the top 10 vaccine varieties worldwide. Notably, the recombinant HBV vaccines and freeze-dried human rabies vaccines are our key commercialized market-leading vaccine products, making AIM Vaccine the largest hepatitis B vaccine manufacturer and the second-largest rabies vaccine manufacturer globally.

Among them, the recombinant hepatitis B vaccine is and is expected to continue as a major type of commercialized product for AIM Vaccine. Currently, AIM is the first and only company in China with steady production and approved lot release of HBV vaccines using Hansenula Polymorpha for antigen expression. Since its approval, recombinant HBV vaccine series products have maintained a 100% pass rate in lot release quality audits of NIFDC. With the shift from universal newborn vaccination to vaccination for the entire population, hepatitis B vaccination presents a new growth opportunity for the company.

The freeze-dried human rabies vaccine (Vero cell), known for its high quality and stability, remains a key competitive factor in the market. Since its commercialization in 2007, AIM’s production of the lyophilized human rabies vaccine (Vero cell) has maintained a 100% approval rate in batch release inspections by the NIFDC for the past 16 years.

Following the established corporate strategy of the Company, AIM Vaccine proactively advance the development of the vaccine pipelines and accelerate the research and development of iterative pneumonia series vaccines through on-going technological innovation, achieving new productive forces at an accelerated pace. Leveraging the advantages of the polysaccharide conjugate vaccine technology platform, AIM Vaccine have developed a series of pneumonia vaccines, including: (1) the 13-valent pneumonia conjugate vaccine, which has completed on-site work for Phase III clinical trial and has submitted a pre-application for marketing; (2) the 23-valent pneumonia polysaccharide vaccine, which has also completed Phase III clinical trial and is expected to apply for marketing registration in 2024; (3) the 20-valent pneumonia conjugate vaccine, which has submitted a preapplication for clinical trials; and (4) the 24-valent pneumonia conjugate vaccine, which is being simultaneously developed globally for the first time and has completed preclinical research.

In the layout of the rabies vaccine series, AIM is leading the deep technological iteration and upgrade of global rabies vaccines, aiming to provide the market with upgraded and advanced rabies vaccine products that offer better quality, higher safety, and require fewer doses for administration. This will further strengthen the company’s competitiveness in the rabies vaccine market. The on-site work of the Phase III clinical trial of iterative serum-free rabies vaccine has been completed, and various preparatory work for the new drug marketing application is underway, which is planned to be completed in 2024; The CTA for the novel-process highly-effective human diploid rabies vaccine is expected to be submitted in 2024; and the iterative mRNA rabies vaccine is the first non-COVID-19 mRNA vaccine candidate accepted by relevant authorities in China.

Accelerating Efficient Vaccine Development through a Comprehensive Technological Platform. Rapid Advancement in the Pipeline Layout of mRNA Technology Platform

AIM Vaccine have five proven human vaccine platform technologies covering innovative technologies, such as mRNA vaccine, genetically engineered vaccine, and combination vaccine technologies, as well as traditional technologies, such as bacterial vaccine and viral vaccine technologies. Leveraging these platforms, we are well positioned to develop a steady and fit-for-purpose stream of vaccines that are efficient to manufacture. We have at least one approved product or one vaccine candidate at CTA or clinical stages under each platform. At the same time, the Company is currently designing the structure of antigens and mRNA sequence of vaccines leveraging artificial intelligence, and is trying to leverage artificial intelligence to assist in process research and development of vaccines. Looking forward, the Company expects to increase the depth of existing applications and expand its applications in clinical trial data analysis.

Notably, AIM Vaccine’s mRNA technology platform has been validated through clinical trial data from tens of thousands of subjects. The safety and efficacy of platform products have been thoroughly demonstrated. AIM Vaccine has developed several mRNA COVID-19 vaccines that have undergone clinical trials, allowing for accelerated development and registration of products. Within this platform, AIM has developed the mRNA iterative rabies vaccine, which is the first non-COVID mRNA vaccine product accepted domestically in China. Two other highly anticipated products, the mRNA respiratory syncytial virus (RSV) vaccine and mRNA herpes zoster vaccine, are expected to complete clinical trial applications in 2024.

Additionally, AIM Vaccine have submitted pre-applications to the NMPA for clinical trials of the Company’s 20-valent pneumonia conjugate vaccine (PCV20), haemophilus influenzae type b (Hib) conjugate vaccine, adsorbed tetanus vaccine, quadrivalent influenza virus vaccine (MDCK Cells) and novel-process highly-effective human diploid rabies vaccine. AIM Vaccine has also submitted a preclinical trial application for its quadrivalent MDCK cell-based influenza vaccine, which is currently under development.

Future Outlook: Strengthening Monopoly Advantage and Expanding International Market for Global Vaccine Shortages.

In recent years, the vaccine industry in China has strengthened the monopoly advantage of vaccines in disease prevention, elevated the status of vaccines in the overall biomedical industry, and facilitated the industrialization of new technologies for biotechnology and the implementation of related policies, establishing a foundation for the long-term development of the vaccine industry. The significant increase in exports of vaccines has greatly boosted the confidence of Chinese pharmaceutical companies in their international expansion.

Furthermore, in order to accelerate the promotion of internationalized business, the Company specifically set up an international business department to push forward the implementation of series of internationalized layout, and is ready in all aspects such as overseas marketing permission, product research and development and manufacturing. The Company’s vaccine products are entering the global market.

At present, the Company has various specific overseas markets and has begun the registration of marketed products in regions such as Southeast Asia, Africa, South America and the Middle East. The Company’s rabies vaccine has obtained the registration licenses in countries such as Pakistan.

In terms of products under development, the Company has set up product pipelines with close reference to the needs of the international market. In accordance with the latest World Health Organization’s vaccine prequalification list (2024-2026), the Company is rapidly promoting the research and development of the 13-valent pneumonia conjugate vaccine and the tetravalent meningococcal conjugate vaccine, both being high-priority qualified vaccines. In addition, the Company is proactively researching and developing the RSV vaccine and the shingles/herpes zoster vaccine, both of which are also the varieties in short supply in the international market. The Company is making efforts to promote the marketing registration and sale of these products within and outside China, and to achieve the World Health Organization’s prequalification for the vaccines.

In terms of on-sale products, HAV vaccine, HBV vaccine and rabies vaccine launched by the Company are medium-priority qualified products by the Word Health Organization, all of which are welcomed in the international market.

In terms of production capacity construction, the Company has completed construction of GMP workshops for iterative pneumonia series vaccines and iterative rabies series vaccines in batches, and all of these workshops meet the international standards. Phase III clinical samples of 13-valent pneumonia conjugate vaccine and 23-valent pneumonia polysaccharide vaccine are produced in these workshops, helping the Company get fully ready for the quick entry into the overseas market of such products upon marketing.

With the increase in China’s economic strength, the biopharmaceutical industry, including the vaccine sector, has been identified as a strategic emerging industry and is encouraged and supported by the national government. Therefore, AIM Vaccine has entered a period of intense application for major upgraded products in 2024. Three significant products are expected to complete the application process and be launched within the year, which is projected to drive substantial revenue growth for the company.
Hashtag: #AIMVaccine

The issuer is solely responsible for the content of this announcement.

About AIM Vaccine Co., Ltd.

AIM Vaccine (stock code: 06660) is committed to manufacturing conscientious vaccines and promoting the health of the people. It is the second-largest vaccine group in China and the largest private-sector vaccine group, with a complete industry chain. AIM Vaccine is a leading company in the Chinese vaccine industry and one of the top players in the mRNA vaccine field. As one of the most strictly regulated industries in the country, China has over 40 vaccine production qualifications nationwide. Currently, AIM Vaccine owns four wholly-owned licensed vaccine production companies and three vaccine research institutes. It is one of the only two human vaccine companies in China with strategic resources such as P3 laboratories. AIM Vaccine is also the world’s largest manufacturer of hepatitis B vaccines and the second-largest manufacturer of rabies vaccines globally.

AIM Vaccine has a portfolio of eight commercialized vaccines and 21 vaccines under development, covering the top ten vaccine varieties globally. Its commercialized products have maintained a leading market position for a long time, with sales covering all 31 provinces, municipalities, and autonomous regions in China, reaching over 2,000 district and county-level disease control centers.

MUNICH, GERMANY – Media OutReach Newswire – 28 March 2024 – Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) and HD Korea Shipbuilding & Offshore Engineering Co. Ltd. (HD KSOE) have signed a non-binding Memorandum of Understanding (MoU) as a first step towards jointly developing emerging applications for the electrification of marine engines and machinery using energy-efficient power semiconductor technology.

HD KSOE, a marine pioneer and global leader in ship building, is already focusing on creating eco-friendly decarbonized ship technology that uses electricity and hydrogen. The company will now cooperate with Infineon to create innovative power solutions for propulsion drive technology, a core element for ship electrification. Power semiconductors from Infineon drive the transformation towards clean, safe, and smart mobility services across all means of transportation. For modern maritime applications they are a key factor in guaranteeing a precise control of multiple power modules, such as large-capacity propulsion drives.

Infineon will provide HD KSOE with technical assistance and mentoring in semiconductor power modules and system solutions, as well as share information on new semiconductor trends for marine applications. With the partnership HD KSOE aims to enhance reliability and performance of marine vessels’ propulsion drive technology contributing to environmental sustainability through the electrification of ships.

Worldwide, maritime transport is responsible for almost 2.5 percent of total greenhouse gas emissions, according to the International Maritime Organization. It produces one billion tons of CO₂ each year. The transition to electric ships is imperative to mitigate the environmental impact of maritime transportation.

“We are pleased to sign an MoU with Infineon, which underpins our innovation efforts to become a leader in ship electrification technology,” said Chang Kwang-pil, Chief Technology Officer of HD KSOE. “Together, we will combine our strengths to create energy-efficient power solutions for CO2-friendly propulsion drives.”

“At Infineon we are providing the technologies needed in today’s world of transportation to drive electrification that will shape the future of mobility,” said Dr. Peter Wawer, Division President Green Industrial Power at Infineon Technologies. “We are excited to work closely together with HD KSOE to develop clean, safe and smart mobility solutions. This way, we contribute to a more sustainable marine engine ecosystem and drive the decarbonization of shipping.”

Hashtag: #Infineon #electrification #sustainability #powersemiconductor

https://www.infineon.com/
https://www.linkedin.com/company/infineon-technologies/
https://www.facebook.com/infineon

The issuer is solely responsible for the content of this announcement.

About Infineon

Infineon Technologies AG is a global semiconductor leader in power systems and IoT. Infineon drives decarbonization and digitalization with its products and solutions. The company has around 58,600 employees worldwide and generated revenue of about €16.3 billion in the 2023 fiscal year (ending 30 September). Infineon is listed on the Frankfurt Stock Exchange (ticker symbol: IFX) and in the USA on the OTCQX International over-the-counter market (ticker symbol: IFNNY).